Cooper Companies (NASDAQ:COO) Price Target Cut to $73.00 by Analysts at Needham & Company LLC

Key Points

• Needham cut Cooper Companies’ price target from $86 to $73 but maintained a “buy” rating, implying about 15% upside from the prior close. The broader analyst consensus is “hold,” with an average target of $75.27.
• Cooper Companies reported adjusted EPS of $1.15, slightly ahead of expectations, but revenue of approximately $1.07 billion fell short of forecasts. The company lowered fiscal 2026 adjusted EPS guidance to $4.51–$4.55, below the roughly $4.63 consensus.
• The board authorized a $3 billion share-repurchase program, allowing buybacks of up to 22.7% of outstanding shares. However, the strategic review will retain CooperSurgical after potential offers were deemed insufficient, disappointing investors seeking a value-unlocking sale.

Cooper Companies (NASDAQ:COO - Get Free Report) had its price objective dropped by equities researchers at Needham & Company LLC from $86.00 to $73.00 in a report issued on Thursday, MarketBeat.com reports. The brokerage currently has a "buy" rating on the medical device company's stock. Needham & Company LLC's price objective suggests a potential upside of 15.00% from the stock's previous close.

Several other equities research analysts have also recently weighed in on COO. UBS Group started coverage on shares of Cooper Companies in a research report on Tuesday, July 28th. They set a "neutral" rating and a $75.00 price objective for the company. KeyCorp reaffirmed a "sector weight" rating on shares of Cooper Companies in a research report on Friday, June 5th. The Goldman Sachs Group set a $61.00 price target on Cooper Companies in a report on Wednesday, May 27th. Mizuho set a $85.00 price objective on Cooper Companies and gave the stock an "outperform" rating in a research report on Thursday, June 4th. Finally, Wells Fargo & Company restated a "sell" rating and set a $66.00 target price (down from $82.00) on shares of Cooper Companies in a research report on Friday, June 5th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, nine have given a Hold rating and three have issued a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Hold" and an average target price of $75.27.

Cooper Companies Price Performance

Shares of COO opened at $63.48 on Thursday. The company has a quick ratio of 0.78, a current ratio of 1.27 and a debt-to-equity ratio of 0.23. The stock has a market cap of $12.38 billion, a PE ratio of 53.80, a PEG ratio of 1.77 and a beta of 0.82. Cooper Companies has a 12-month low of $58.89 and a 12-month high of $89.83. The business has a 50-day simple moving average of $72.42 and a two-hundred day simple moving average of $70.02.

Cooper Companies (NASDAQ:COO - Get Free Report) last issued its quarterly earnings results on Wednesday, September 9th. The medical device company reported $1.15 EPS for the quarter, topping analysts' consensus estimates of $1.12 by $0.03. The company had revenue of $1.07 billion for the quarter, compared to analyst estimates of $1.10 billion. Cooper Companies had a net margin of 5.57% and a return on equity of 10.88%. Cooper Companies's revenue was up .5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.49 earnings per share. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. Analysts anticipate that Cooper Companies will post 4.63 earnings per share for the current fiscal year.

Cooper Companies declared that its Board of Directors has authorized a stock buyback plan on Wednesday, September 9th that allows the company to repurchase $3.00 billion in outstanding shares. This repurchase authorization allows the medical device company to buy up to 22.7% of its shares through open market purchases. Shares repurchase plans are often an indication that the company's board believes its shares are undervalued.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the company. California State Teachers Retirement System boosted its holdings in Cooper Companies by 6,101.7% during the second quarter. California State Teachers Retirement System now owns 19,460,014 shares of the medical device company's stock worth $1,395,478,000 after purchasing an additional 19,146,230 shares during the last quarter. BlackRock Inc. purchased a new stake in Cooper Companies in the 2nd quarter valued at about $1,077,762,000. Generation Investment Management LLP bought a new position in shares of Cooper Companies during the 2nd quarter worth approximately $356,304,000. Wellington Management Group LLP lifted its position in shares of Cooper Companies by 332.9% during the 3rd quarter. Wellington Management Group LLP now owns 6,184,992 shares of the medical device company's stock worth $424,043,000 after buying an additional 4,756,178 shares in the last quarter. Finally, Jupiter Topco LLC purchased a new position in shares of Cooper Companies in the 2nd quarter worth approximately $305,074,000. 24.39% of the stock is owned by institutional investors.

Trending Headlines about Cooper Companies

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: CooperCompanies reported fiscal third-quarter adjusted EPS of $1.15, ahead of the $1.11–$1.12 analyst consensus. Revenue reached approximately $1.066 billion, while free cash flow increased 66% to $273 million. CooperCompanies Announces Third Quarter 2026 Results
• Positive Sentiment: The board expanded its share-repurchase authorization from $2 billion to $3 billion, potentially allowing the company to buy back as much as 22.7% of outstanding shares. Management also repurchased $339.1 million of stock during the quarter, supporting per-share value if executed effectively. CooperCompanies Completes Strategic Review
• Neutral Sentiment: GAAP EPS was $2.24, helped substantially by a $307.2 million discrete tax benefit related to the favorable completion of a U.K. tax examination. This benefit improves reported results but is not representative of recurring operating performance. CooperCompanies Reports Third-Quarter Results
• Negative Sentiment: CooperCompanies lowered fiscal 2026 adjusted EPS guidance to $4.51–$4.55, below the roughly $4.63 consensus, and set fourth-quarter EPS guidance at $1.05–$1.09 versus expectations near $1.20. Full-year revenue guidance of $4.229–$4.252 billion also implies modest growth.
• Negative Sentiment: The strategic review concluded that CooperSurgical will be retained because potential offers were not sufficiently attractive. Investors appear disappointed that the company did not unlock value through a sale, particularly amid fertility-related litigation costs and competitive pressure in the IUD market. Reasons Cooper Companies Stock Is Under Pressure

Cooper Companies Company Profile

Cooper Companies, Inc is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company develops, manufactures and markets products through two primary business segments: CooperVision and CooperSurgical.

CooperVision specializes in contact lenses, including daily disposable, toric, multifocal, multifocal toric, specialty and myopia-management lenses. Its products are designed to address a range of vision-correction needs, including astigmatism, presbyopia and irregular corneas.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.